Cargando…
Severe Refractory Hypocalcemia Caused by Denosumab
Denosumab is a fully human monoclonal antibody that binds to the receptor activator of nuclear factor kappa-Β ligand, an essential cytokine factor in bone resorption, which reduces bone resorption and has been shown to decrease the incidence of skeletal-related events in patients with malignancy and...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315058/ https://www.ncbi.nlm.nih.gov/pubmed/37404446 http://dx.doi.org/10.7759/cureus.39866 |
_version_ | 1785067433830121472 |
---|---|
author | Dadana, Sriharsha Gundepalli, Sai Kondapalli, Anusha |
author_facet | Dadana, Sriharsha Gundepalli, Sai Kondapalli, Anusha |
author_sort | Dadana, Sriharsha |
collection | PubMed |
description | Denosumab is a fully human monoclonal antibody that binds to the receptor activator of nuclear factor kappa-Β ligand, an essential cytokine factor in bone resorption, which reduces bone resorption and has been shown to decrease the incidence of skeletal-related events in patients with malignancy and bone metastasis. Severe hypocalcemia is a rare and life-threatening adverse effect of denosumab therapy. Here, we discuss the case of a patient with stage 4 estrogen receptor-positive, progesterone receptor-negative, human epidermal growth factor receptor 2-negative breast cancer who was on treatment with denosumab for bony metastases and presented with severe refractory hypocalcemia. |
format | Online Article Text |
id | pubmed-10315058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-103150582023-07-03 Severe Refractory Hypocalcemia Caused by Denosumab Dadana, Sriharsha Gundepalli, Sai Kondapalli, Anusha Cureus Endocrinology/Diabetes/Metabolism Denosumab is a fully human monoclonal antibody that binds to the receptor activator of nuclear factor kappa-Β ligand, an essential cytokine factor in bone resorption, which reduces bone resorption and has been shown to decrease the incidence of skeletal-related events in patients with malignancy and bone metastasis. Severe hypocalcemia is a rare and life-threatening adverse effect of denosumab therapy. Here, we discuss the case of a patient with stage 4 estrogen receptor-positive, progesterone receptor-negative, human epidermal growth factor receptor 2-negative breast cancer who was on treatment with denosumab for bony metastases and presented with severe refractory hypocalcemia. Cureus 2023-06-02 /pmc/articles/PMC10315058/ /pubmed/37404446 http://dx.doi.org/10.7759/cureus.39866 Text en Copyright © 2023, Dadana et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Endocrinology/Diabetes/Metabolism Dadana, Sriharsha Gundepalli, Sai Kondapalli, Anusha Severe Refractory Hypocalcemia Caused by Denosumab |
title | Severe Refractory Hypocalcemia Caused by Denosumab |
title_full | Severe Refractory Hypocalcemia Caused by Denosumab |
title_fullStr | Severe Refractory Hypocalcemia Caused by Denosumab |
title_full_unstemmed | Severe Refractory Hypocalcemia Caused by Denosumab |
title_short | Severe Refractory Hypocalcemia Caused by Denosumab |
title_sort | severe refractory hypocalcemia caused by denosumab |
topic | Endocrinology/Diabetes/Metabolism |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315058/ https://www.ncbi.nlm.nih.gov/pubmed/37404446 http://dx.doi.org/10.7759/cureus.39866 |
work_keys_str_mv | AT dadanasriharsha severerefractoryhypocalcemiacausedbydenosumab AT gundepallisai severerefractoryhypocalcemiacausedbydenosumab AT kondapallianusha severerefractoryhypocalcemiacausedbydenosumab |